Okairos: Okay After All
On May 29th, 2013, GlaxoSmithKline (GSK) announced the acquisition of Okairos in an all-cash deal worth $325 million US. The Okairos acquisition helps complement the pharma giant’s existing vaccine technology and expertise and will enable GSK to continue its work developing the next generation of vaccines.
Read more »Researchers, Healthcare Companies Seek to Give COPD Patients Some Breathing Room
Breathing is one of the most basic human functions, but for an estimated 12 million people in the United States, the simple act of drawing a breath can be difficult and even painful.
Read more »Pharmaceutical Companies Eye India
On May 21, Abbott Laboratories announced that it would purchase Piramal Healthcare, a branded generics company based in India, for $3.72 billion.
Read more »Nabi Tries to Help Smokers Break the Habit
“Quitting smoking” is one of the most popular New Year’s resolutions, right up there with “losing weight” and “exercising more.”
Read more »FDA Calendar November Stocks: Turkeys or a Happy Thanksgiving?
On 10/19/09, BioElectronics (OTC: BIEL.PK) announced the initial results from the pilot section of its ongoing acetaminophen comparison study.
Read more »Another Company Announces Positive Lupus Drug Data
Immunomedics has become the second biopharmaceutical company in recent weeks to announce a successful trial of its lupus drug.
Read more »DATATRAK Awarded Phase III Trial With Top 20 Pharma Company
DATATRAK International, a provider of technical support systems for clinical studies, has been awarded a Phase III clinical trial by the European division of a Global Top 20 pharmaceutical company.
Read more »GSK and Enigma Pair Up to Develop Influenza Diagnostics
The new test would analyze swab samples and return a diagnosis in less than 60 minutes.
Read more »Human Genome’s Lupus Drug Surprises Analysts
Shares in Human Genome Sciences increased by 277 percent on Monday after the company announced that their lupus drug Benlysta succeeded in a Phase III clinical trial.
Read more »